Page 146 - வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Now more people can get lung cancer screening
dailyrepublicannews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrepublicannews.com Daily Mail and Mail on Sunday newspapers.
Kennedy Krieger Institute offers COVID-19 testing at its schools
thedailyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailyrecord.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Professor of human genetics and epidemiology, University of Pittsburgh Graduate School of Public Health. view more
Credit: University of Pittsburgh
PITTSBURGH, May 5, 2021 - Despite decades of research and investment, the genetic underpinnings of Alzheimer s disease are still largely unknown, stymieing drug development and early diagnosis efforts. A new $10.7 million, five-year project led by the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine in St. Louis aims to change that with the first comprehensive study using whole genome sequencing to address a critical gap in knowledge about the disease.
With funding from the National Institute on Aging, the research team plans to identify the genetic variants, genes and pathways that lead to formation of plaques and tangles, two specific biomarkers that begin accumulating in the brains of people with Alzheimer s 15 to 25 years before they show symptoms.
Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023 Conference Call Today at 4:30 p.m. (ET)
News provided by
Share this article
Share this article
ROCKVILLE, Md., May 5, 2021 /PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2021.
vimarsana © 2020. All Rights Reserved.